The sector decisively has pushed through upward resistance levels in place for many months.
Two are turnaround stories, and two are oversold.
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.